| Evidence for a window of enhanced plasticity in the human motor cortex following ischemic stroke B Hordacre, D Austin, KE Brown, L Graetz, I Pareés, S De Trane, ... Neurorehabilitation and neural repair 35 (4), 307-320, 2021 | 39 | 2021 |
| Treating the ineligible: disease modification in people with multiple sclerosis beyond NHS England commissioning policies Z Mao, C Álvarez-González, K Allen-Philbey, S De Trane, O Yildiz, ... Multiple Sclerosis and Related Disorders 27, 247-253, 2019 | 12 | 2019 |
| Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? Z Mao, C Álvarez-Gonzalez, S De Trane, O Yildiz, C Albor, G Doctor, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 4 (2 …, 2018 | 12 | 2018 |
| Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? M Mateo-Casas, S Reyes, S De Trane, F Edwards, M Espasandin, ... Eneurologicalsci 21, 100279, 2020 | 6 | 2020 |
| Severe skin reactions associated with cladribine in people with multiple sclerosis M Mateo-Casas, S Reyes, EA O'Toole, S De Trane, O Yildiz, ... Multiple Sclerosis and Related Disorders 43, 102140, 2020 | 6 | 2020 |
| Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients K Allen-Philbey, S De Trane, Z Mao, C Álvarez-González, J Mathews, ... Therapeutic advances in neurological disorders 14, 17562864211057661, 2021 | 5 | 2021 |
| Cladribine personalised dosing in people with MS (n> 200)-four years experience in clinical care. S De Trane, Z Mao, C Alvarez-Gonzalez, K Allen-Philbey, O Yildiz, ... | 2 | 2018 |
| Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis K Allen-Philbey, S De Trane, A MacDougall, A Adams, L Bianchi, ... Therapeutic Advances in Neurological Disorders 16, 17562864231200627, 2023 | 1 | 2023 |
| Are poor depleters worse off? Variation in total lymphocyte reduction following MS treatment with cladribine C Cores, S Reyes, S De Trane, G Giovannoni, K Schmierer, D Baker MULTIPLE SCLEROSIS JOURNAL 25, 745-746, 2019 | 1 | 2019 |
| THC: CBD (Nabiximols) has a beneficial effect on resistant MS related spasticity and reduces the need for Intrathecal baclofen S De Trane, K Buchanan, L Keenan, S Simeoni, LO Brien, V Stevenson, ... Multiple Sclerosis Journal 23, 1012-1013, 2017 | 1 | 2017 |
| Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells F Ammoscato, M Aboulwafa, J Skonieczna, J Bestwick, R Monero, ... medRxiv, 2024.03. 28.24304956, 2024 | | 2024 |
| Personalised immunotherapy in active multiple sclerosis using injectable cladrib-ine: Follow-up of the BartsMS cohort K Allen-Philbey, S De Trane, O Yildiz, A Adams, B Turner, M Marta, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A2-A2, 2022 | | 2022 |
| Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528) K Allen-Philbey, S De Trane, A Stennett, O Yildiz, A Adams, B Turner, ... Neurology 96 (15 Supplement), 2021 | | 2021 |
| Up to 6 years follow-up of people with MS (n= 250) receiving cladribine K Allen-Philbey, S De Trane, A Stennett, O Yildiz, A Adams, B Turner, ... Multiple Sclerosis Journal, 546-547, 2021 | | 2021 |
| Cladribine Personalised Dosing to Treat Active Multiple Sclerosis-Follow-up in 250 patients K Allen-Philbey, S De Trane, A Stennett, O Yildiz, A Adams, B Turner, ... | | 2021 |
| Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients K Allen-Philbey, S De Trane, A Stennett, O Yildiz, A Adams, B Turner, ... | | 2020 |
| Cladribine at all stages of MS: two-year follow-up in 154 patients S De Trane, K Allen-Philbey, A Stennett, O Yildiz, A Adams, B Turner, ... MULTIPLE SCLEROSIS JOURNAL 25, 519-520, 2019 | | 2019 |
| Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4. 2-022) M Mateo-Casas, S Reyes, S De Trane, O Yildiz, B Turner, J Mathews, ... Neurology 92 (15 Supplement), 2019 | | 2019 |
| Cladribine to treat Relapsing and Progressive Multiple Sclerosis-experience in> 200 patients (S26. 008) S De Trane, Z Mao, C Alvarez-Gonzalez, K Allen-Philbey, O Yildiz, ... Neurology 92 (15_supplement), S26. 008, 2019 | | 2019 |
| PO123 Thc: cbd (nabiximols) has a beneficial effect on multiple sclerosis related spasticity and delays the need for intrathecal baclofen S De Trane, K Buchanan, L Keenan, C Valentine, M Liddicut, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (Suppl 1), A44-A44, 2017 | | 2017 |
Klaus SchmiererThe Blizard Institute, Queen Mary University of London, Medicine & Dentistry//Barts Health NHS TrustVerified email at qmul.ac.uk
